Загрузка...
Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
BACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline characteristics. Data on treating HCV GT4 with LDV/...
Сохранить в:
| Опубликовано в: : | Saudi J Gastroenterol |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Medknow Publications & Media Pvt Ltd
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6373216/ https://ncbi.nlm.nih.gov/pubmed/30117490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sjg.SJG_189_18 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|